Clinical Trial Search

Primary: Number of Participants With Complete Responses (CRs), Partial Responses (PRs,) Stable Disease and Progressive Disease in the Ovarian Cancer and Breast Cancer Cohorts…

Primary: Number of Participants With Fusion — 50 Participants

Primary: Montgomery-Asberg Depression Rating Scale Comparison to Baseline — 29.50; 15.83 units on a scale

Primary: The Percent Change in Bilateral Thigh Lean Mass Density (Grams) as Measured by DEXA Scan Will be Compared Between Baseline and After 5-days of Bed Rest — -3.845; -0.249…

Primary: Percentage of Subjects With Investigator-graded Lens Centration of "Optimal" — 97.0; 91.0 percentage of subjects — p=0.0455

Primary: Proportion of Patients Achieving American College of Rheumatology 20 (ACR20) Response Criteria on Secukinumab Versus Placebo at Week 24 — 58; 67; 22 Participants

Primary: Accelerometer-based Moderate-to-vigorous Physical Activity (MVPA) — 144.4; 129.9 minutes/week — p=.03

Primary: Overall Pain in Postoperative Period — 1.6; 2.7 score on a scale — p=0.1459

Primary: Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40 — 0; 0; 0; 0 Participants

Primary: Number of Participants With Objective Response — 1; 2; 14; 6 Participants

Primary: Visual Aanalog Scale (VAS) for Pain Assessment With Cough at 48 Hours — 1.7; 3.9 units on a scale — p=.0022

Primary: Percentage of Participants With Fusion — 99.1 Percentage of Participants

Primary: Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) — 2.35; 1.28; 1.37…

Primary: Bacterial Clearance Rate of Sputum — 38; 16 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Entire…